• Ascend Wellness posted Q1 2026 net loss of USD 29.5 million, narrowing from USD 48.7 million in Q4 2025; net revenue slipped 3% sequentially to USD 116.9 million.
• Adjusted EBITDA fell to USD 26.3 million from USD 30.2 million, with margin steady at 22.5%.
• Cash and cash equivalents ended quarter at USD 60.9 million; net cash used in operating activities was USD 19.4 million, including a USD 19.1 million bi-annual interest payment under 2024 indenture and a USD 17 million arbitration settlement payment.
• Store footprint reached 51 locations with five dispensaries added in 2026; retail pipeline calls for 10 more locations, targeting at least 60 stores by year-end pending approvals.
• Outlook calls for Q2 2026 revenue up 2%-3% with adjusted EBITDA margin holding in low-20% range, as management evaluates potential near-term benefits from expected medical cannabis rescheduling to Schedule III.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascend Wellness Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605131600PR_NEWS_USPR_____TO59006) on May 13, 2026, and is solely responsible for the information contained therein.